Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Even with these adjustments, semaglutide combined with basal insulin led to HbA1c reductions of 1.4% to 1.8% over 30 weeks
full renal and cardiovascular benefits observed by week 24 in clinical trials
Wound and surgical recovery: Accelerated healing, reduced scarring
Recent guidelines by the American Diabetes Association and the European Association for the Study of Diabetes recommend that for most such patients, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are preferable to insulin as the initial injection therapy and are also the preferred choice for addition to basal insulin for combination injection therapy [3]
We provide medical care, with the medication as part of it
.png)
Tirzepatide (going by the brand names Mounjaro and Zepbound) is the only dual agonist currently approved in Canada
